Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cytokinetics
ClinicalTrials.gov Identifier:
NCT01378676
First received: June 20, 2011
Last updated: September 16, 2013
Last verified: March 2012
  Purpose

The study will generate data on safety and tolerability after multiple daily doses of CK-2017357 in patients with ALS. Patients will be randomized into one of four different treatment groups, receiving daily oral doses of either placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for 14 days.


Condition Intervention Phase
Amyotrophic Lateral Sclerosis
Drug: Placebo
Drug: CK-2017357
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Resource links provided by NLM:


Further study details as provided by Cytokinetics:

Primary Outcome Measures:
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Safety and tolerability of CK-2017357 after multiple oral doses to steady state in patients with ALS


Secondary Outcome Measures:
  • ALSFRS-R [ Time Frame: 21 days ] [ Designated as safety issue: No ]
  • Measurement of muscle fatigue [ Time Frame: 21 days ] [ Designated as safety issue: No ]
  • Measurement of pulmonary function [ Time Frame: 21 days ] [ Designated as safety issue: No ]
  • Patient global assessment [ Time Frame: 21 days ] [ Designated as safety issue: No ]
  • Investigator global assessment [ Time Frame: 21 days ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: June 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Matching Placebo Drug: Placebo
Three matching placebo tablets once daily for 14 days (Part A) or three matching placebo tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
Experimental: Active Drug Low Dose Drug: CK-2017357
One 125 mg CK-2017357 tablet and two matching placebo tablets once daily for 14 days (Part A) or one 125 mg CK-2017357 tablet and two matching placebo tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
Other Name: tirasemtiv
Experimental: Active Drug Mid Dose Drug: CK-2017357
Two 125 mg CK-2017357 tablets and one matching placebo tablet once daily for 14 days (Part A) or two 125 mg CK-2017357 tablets and one matching placebo tablet once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
Experimental: Active Drug High Dose Drug: CK-2017357
Three 125 mg CK-2017357 tablets once daily for 14 days (Part A) or three 125 mg CK-2017357 tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)

Detailed Description:

In Part A, approximately 24 patients will be randomized to one of four different treatment groups. After a 7-day washout of riluzole, patients in each treatment group will receive daily oral doses of placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for 14 days. Patients will take daily doses of CK-2017357 or placebo (Day 1 through Day 14) and will return to the study site on Day 2, Day 8 and Day 15. All patients will return for a follow-up visit 7 days (± 2 days) after their last dose.

In Part B, approximately 24 patients will be randomized to one of four different treatment groups as in Part A. Patients in Part B will be required to decrease their riluzole dose to 50 mg once a day (QD) for 7 days prior to randomization. After this 7 day period, patients will take riluzole at 50 mg QD concurrently with their morning dose of blinded study drug.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Able to comprehend and willing to sign an Informed Consent Form (ICF)
  2. Males or females 18 years of age or older
  3. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria)
  4. Maximum voluntary grip strength in at least one hand between 10 & 40 pounds (females) and 10 & 60 pounds (males)
  5. Upright Slow Vital Capacity (SVC) >50% of predicted for age, height, and sex
  6. Able to swallow tablets with water
  7. Willing and able to remain off riluzole for 4 weeks (Part A only)
  8. Currently taking and tolerating a stable dose of 50 mg BID riluzole (Part B only)
  9. Willing and able to reduce daily dose of riluzole to 50 mg for 4 weeks (Part B only)
  10. Willing and able to refrain from caffeine-containing products during study participation
  11. Willing and able to remain off warfarin and theophylline-containing medications during study participation
  12. Has a caregiver who is capable of observing and reporting patient status, and also assisting in the proper use of nocturnal oximetry equipment
  13. Able to perform pulmonary function tests

Key Exclusion Criteria:

  1. Life expectancy <3 months
  2. Participation in any trial in which receipt of investigational study drug occurred within 30 days or 5 half-lives of the prior agent, whichever is greater, prior to dosing
  3. Any prior treatment with CK-2017357
  4. Use of non-invasive positive pressure ventilation (NIPPV) for any part of the day or night

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01378676

Locations
United States, California
California Pacific Medical Center
San Francisco, California, United States, 94115
United States, Florida
Mayo Florida
Jacksonville, Florida, United States, 32224
United States, Kansas
University of Kansas
Kansas City, Kansas, United States, 06053
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
SUNY Upstate Medical Center
Syracuse, New York, United States, 13210
United States, North Carolina
Carolinas Neuromuscular ALS-MND Center
Charlotte, North Carolina, United States, 28207
United States, Pennsylvania
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Drexel University College of Medicine
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Cytokinetics
Investigators
Study Chair: Jeremy Shefner, MD, PhD State University of New York - Upstate Medical University
  More Information

No publications provided

Responsible Party: Cytokinetics
ClinicalTrials.gov Identifier: NCT01378676     History of Changes
Other Study ID Numbers: CY 4024
Study First Received: June 20, 2011
Last Updated: September 16, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Sclerosis
Central Nervous System Diseases
Metabolic Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
Pathologic Processes
Proteostasis Deficiencies
Spinal Cord Diseases
TDP-43 Proteinopathies

ClinicalTrials.gov processed this record on November 24, 2014